Three new potential cAMP affinity labels. Inactivation of human platelet low Km cAMP phosphodiesterase by 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic monophosphate.
Three new analogues of cAMP have been synthesized and characterized: 2-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic monophosphate (2-BDB-TcAMP), 2-[(3-bromo-2-oxopropyl)thio]-adenosine 3',5'-cyclic monophosphate (2-BOP-tcAMP), and 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic monophosphate (8-BDB-TcAMP). The bromoketo moiety has the ability to react with the nucleophilic side chains of several amino acids, while the dioxobutyl group can interact with arginine. These cAMP analogues were tested for their ability to inactivate the low Km (high affinity) cAMP phosphodiesterase from human platelets. The 2-BDB-TcAMP and 2-BOP-TcAMP were competitive inhibitors of cAMP hydrolysis by the phosphodiesterase with Ki values of 0.96 +/- 0.12 and 0.70 +/- 0.12 microM, respectively. However, 2-BDB-TcAMP and 2-BOP-TcAMP did not irreversibly inactivate the phosphodiesterase at pH values from 6.0 to 7.5 and at concentrations up to 10 mM. These results indicate that although the 2-substituted TcAMP analogues bind to the enzyme, there are no reactive amino acids in the vicinity of the 2-position of the cAMP binding site. In contrast, incubation of the platelet low Km cAMP phosphodiesterase with 8-BDB-TcAMP resulted in a time-dependent, irreversible inactivation of the enzyme with a second-order rate constant of 0.031 +/- 0.009 min-1 mM1. Addition of the substrates, cAMP and cGMP, and the product, AMP, to the reaction mixture resulted in marked decreases in the inactivation rate, suggesting that the inactivation was due to reaction at the active site of the phosphodiesterase.(ABSTRACT TRUNCATED AT 250 WORDS)
Grant
P G
PG
Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
DeCamp
D L
DL
Bailey
J M
JM
Colman
R W
RW
Colman
R F
RF
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000097:blood*; D000345:Affinity Labels / Q000138:chemical synthesis*; D001665:Binding Sites; D001792:Blood Platelets / Q000201:enzymology; D055598:Chemical Phenomena; D002621:Chemistry; D000242:Cyclic AMP / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D004789:Enzyme Activation; D005069:Evaluation Studies as Topic; D006801:Humans; D007700:Kinetics; D013873:Thionucleotides / Q000138:chemical synthesis / Q000378:metabolism
D000345:Affinity Labels; D013873:Thionucleotides; C064134:2-((4-bromo-2,3-dioxobutyl)thio)-adenosine 3'5'-cyclic monophosphate; C064133:8-((4-bromo-2,3-dioxobutyl)thio)-adenosine 3',5'-cyclic monophosphate; C064135:2-((3-bromo-2-oxopropyl)thio)-adenosine 3'5'-cyclic monophosphate; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases